[A20-03] Ramucirumab (hepatocellular carcinoma) - Addendum to Commission A19-73
Last updated 20.03.2020
Commission awarded on 06.01.2020 by the Federal Joint Committee (G-BA).
Adults with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥ 400 ng/mL and who have been previously treated with sorafenib
Conclusion of dossier assessment A19-73 unchanged: proof of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.